Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Perioperative pembrolizumab in locally advanced head and neck cancer].

Bulletin du cancer·2026
Same author

Ischaemic stroke and 5-fluorouracil or capecitabine: A systematic review and meta-analysis of harms and a retrospective study of the WHO pharmacovigilance database.

British journal of pharmacology·2026
Same author

Multi-omics data integration using time-to event endpoint and supervised Cox penalized regression: a comprehensive review.

Clinical and experimental medicine·2026
Same author

Efficacy of buparlisib according to PIK3CA mutation status in recurrent or metastatic head and neck squamous cell carcinoma: A multicenter phase II trial.

Oral oncology·2026
Same author

Outcomes and Treatments of Patients With Non-Small Cell Lung Cancer Who Received Pembrolizumab.

JAMA oncology·2026
Same author

Phase 1b study of ABBV-368, tilsotolimod, budigalimab, and nab-paclitaxel in patients with recurrent/metastatic head and neck squamous cell carcinoma.

Journal for immunotherapy of cancer·2026
Same journal

RETRACTED: Kim et al. The Angiogenesis Inhibitor ALS-L1023 from Lemon-Balm Leaves Attenuates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease Through Regulating the Visceral Adipose-Tissue Function. <i>Int. J. Mol. Sci.</i> 2017, <i>18</i>, 846.

International journal of molecular sciences·2026
Same journal

Correction: Mahmud et al. Thymoquinone Attenuates NF-κβ Signalling Activation in Retinal Pigment Epithelium Cells Under AMD-Mimicking Conditions. <i>Int. J. Mol. Sci.</i> 2025, <i>26</i>, 11473.

International journal of molecular sciences·2026
Same journal

Correction: Borovikov et al. The Twisting and Untwisting of Actin and Tropomyosin Filaments Are Involved in the Molecular Mechanisms of Muscle Contraction, and Their Disruption Can Result in Muscle Disorders. <i>Int. J. Mol. Sci</i>. 2025, <i>26</i>, 6705.

International journal of molecular sciences·2026
Same journal

Correction: Molagoda et al. Flavonoid Glycosides from <i>Ziziphus jujuba</i> var. <i>inermis</i> (Bunge) Rehder Seeds Inhibit α-Melanocyte-Stimulating Hormone-Mediated Melanogenesis. <i>Int. J. Mol. Sci.</i> 2021, <i>22</i>, 7701.

International journal of molecular sciences·2026
Same journal

Correction: Guo et al. Integrated Transcriptomic and Metabolomic Analysis Reveals the Molecular Regulatory Mechanism of Flavonoid Biosynthesis in Maize Roots Under Lead Stress. <i>Int. J. Mol. Sci.</i> 2024, <i>25</i>, 6050.

International journal of molecular sciences·2026
Same journal

Correction: Chang et al. Improvement of Carbon Tetrachloride-Induced Acute Hepatic Failure by Transplantation of Induced Pluripotent Stem Cells Without Reprogramming Factor c-Myc. <i>Int. J. Mol. Sci.</i> 2012, <i>13</i>, 3598-3617.

International journal of molecular sciences·2026
See all related articles

Related Experiment Video

Updated: Jan 24, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.9K

Hyperprogression under Immunotherapy.

Maxime Frelaut1, Christophe Le Tourneau2,3,4, Edith Borcoman5

  • 1Department of Drug Development and Innovation (D3i), Institut Curie, Paris & Saint-Cloud, France. maxime.frelaut@curie.fr.

International Journal of Molecular Sciences
|June 2, 2019
PubMed
Summary
This summary is machine-generated.

Hyperprogression, a rapid disease acceleration under immunotherapy, occurs frequently (4-29%) but lacks a clear definition. Early detection and treatment cessation are crucial for improving patient outcomes in oncology.

Keywords:
hyperprogressionimmunotherapynew patterns of responsepseudoprogressiontreatment beyond progression

More Related Videos

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
16:56

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Published on: August 30, 2014

17.5K
Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
08:06

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

Published on: November 26, 2010

20.2K

Related Experiment Videos

Last Updated: Jan 24, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.9K
Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
16:56

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Published on: August 30, 2014

17.5K
Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
08:06

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

Published on: November 26, 2010

20.2K

Area of Science:

  • Oncology
  • Immunology
  • Radiology

Background:

  • Immunotherapy is a standard oncology treatment.
  • New response patterns, like hyperprogression, are emerging.
  • Hyperprogression lacks a universally accepted definition.

Purpose of the Study:

  • To review existing data on hyperprogression.
  • To analyze reported definitions, predictive factors, and mechanisms.
  • To highlight the clinical impact and need for consensus.

Main Methods:

  • Systematic review of published studies on hyperprogression.
  • Analysis of reported incidence, definitions, and outcomes.
  • Focus on immune checkpoint inhibitor therapy.

Main Results:

  • Hyperprogression incidence ranged from 4% to 29% across studies.
  • Definitions varied, using tumor burden changes or combined criteria.
  • No consistent predictive factors were identified.
  • Hyperprogression is associated with poorer survival.

Conclusions:

  • Hyperprogression is a frequent and impactful response to immunotherapy.
  • A consensus definition is urgently needed.
  • Early cessation of immunotherapy may be warranted upon suspicion.